A Study to Evaluate the Pharmacokinetics of ASC09F in Healthy Subjects After Multiple Doses
Latest Information Update: 12 Jan 2021
Price :
$35 *
At a glance
- Drugs ASC-09/ritonavir (Primary)
- Indications COVID 2019 infections; HIV infections
- Focus Pharmacokinetics
- Sponsors Ascletis
- 07 Jan 2021 Status changed from not yet recruiting to completed.
- 13 Oct 2020 Planned End Date changed from 31 Dec 2023 to 31 Jan 2024.
- 13 Oct 2020 Planned primary completion date changed from 3 Dec 2020 to 3 Jan 2021.